Cargando…

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation

BACKGROUND: The RESTORE study, a multi-national randomized, placebo-controlled study, showed that erdosteine – a muco-active antioxidant that modulates bacterial adhesiveness – reduced the rate and duration of exacerbations in moderate and severe COPD with a history of exacerbations. How much benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Calverley, Peter MA, Page, Clive, Dal Negro, Roberto W, Fontana, Giovanni, Cazzola, Mario, Cicero, Arrigo F, Pozzi, Edoardo, Wedzicha, Jadwiga A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896911/ https://www.ncbi.nlm.nih.gov/pubmed/31819405 http://dx.doi.org/10.2147/COPD.S221852

Ejemplares similares

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study
por: Dal Negro, Roberto W., et al.
Publicado: (2017)

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
por: Calverley, Peter M A, et al.
Publicado: (2022)

Acute Exacerbations of COPD
por: Wedzicha, Jadwiga A.
Publicado: (2009)

Management of exacerbations of COPD
por: Seemungal, Terence, et al.
Publicado: (2003)

Airflow obstruction: is it asthma or is it COPD?
por: Rogliani, Paola, et al.
Publicado: (2016)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Is gastro-oesophageal reflux associated with COPD exacerbations?
por: Wedzicha, Jadwiga A.
Publicado: (2013)

Deprivation, winter season, and COPD exacerbations
por: Donaldson, Gavin C, et al.
Publicado: (2013)

COPD exacerbations: defining their cause and prevention
por: Wedzicha, Jadwiga A, et al.
Publicado: (2007)

The causes and consequences of seasonal variation in COPD exacerbations
por: Donaldson, Gavin C, et al.
Publicado: (2014)

Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent
por: Cazzola, Mario, et al.
Publicado: (2020)

Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Acute Exacerbations of COPD
por: Wedzicha, J.A.
Publicado: (2002)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
por: Song, Qing, et al.
Publicado: (2021)

The role of complement activation in COPD exacerbation recovery
por: Westwood, John-Paul, et al.
Publicado: (2016)

Combination therapy for airflow limitation in COPD
por: Ghanei, Mostafa, et al.
Publicado: (2012)

Strategies for improving outcomes of COPD exacerbations
por: Wilkinson, Tom, et al.
Publicado: (2006)

Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
por: Valipour, Arschang, et al.
Publicado: (2020)

Exacerbation rate, health status and mortality in COPD – a review of potential interventions
por: Seemungal, Terence AR, et al.
Publicado: (2009)

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
por: Cazzola, Mario, et al.
Publicado: (2015)

The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset [Corrigendum]
Publicado: (2022)

Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations
por: Platé, Manuela, et al.
Publicado: (2014)

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
por: Singh, Dave, et al.
Publicado: (2020)

COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma–COPD overlap syndrome
por: Kurashima, Kazuyoshi, et al.
Publicado: (2016)

Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation
por: Grabcanovic-Musija, Fikreta, et al.
Publicado: (2015)

Hypercapnic Failure in Acute Exacerbated COPD Patients: Severe Airflow Limitation as an Early Warning Signal
por: Grünewaldt, Achim, et al.
Publicado: (2022)

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies
por: Wedzicha, Jadwiga A., et al.
Publicado: (2016)

Novel Anti-Inflammatory Approaches to COPD
por: Cazzola, Mario, et al.
Publicado: (2023)

Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients
por: Millares, Laura, et al.
Publicado: (2019)

Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine
por: Rogliani, Paola, et al.
Publicado: (2019)

Not every irreversible airflow obstruction is COPD
por: Baddini-Martinez, José
Publicado: (2016)

COPD discharge bundle and pulmonary rehabilitation referral and uptake following hospitalisation for acute exacerbation of COPD
por: Barker, Ruth E, et al.
Publicado: (2021)

Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation
por: Kitaguchi, Yoshiaki, et al.
Publicado: (2016)

Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD
por: Wilkinson, Tom M.A., et al.
Publicado: (2006)

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization
por: Wu, Ling, et al.
Publicado: (2021)

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
por: Vogelmeier, Claus F, et al.
Publicado: (2018)

Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study
por: Mackay, Alexander J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l9jthdk6q27ua38h3o674lltgn